TickerTalks
Browse all tickers →
TickerTalks›$PRME
PRPRME

Prime Medicine, Inc.

$PRME·$556M·Biotechnology·Healthcare
$3.54-1.8%YTD-14.9%1Y+4.9%
Mentions · last 7 days
2026-08-21: 7 posts2026-08-22: 8 posts169+4%
Price updated 2m ago·X counts updated 9d ago
PRPRME
$PRMEPrime Medicine, Inc.
$3.55-1.80%169 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PRME, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-08-29

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Prime Medicine +200% in 4 days on the gene-editing rotation plus a Beam Therapeutics arbitration win — real prime-editing story building.

Prime Medicine is a gene-editing biotech using "prime editing" — a next-generation CRISPR-derived technology that can rewrite DNA more precisely than classic CRISPR. The setup is a hot-momentum name coiling on a specific sector rotation plus a legal win.

  • The MRNA cancer-vaccine sector-rotation is the fresh catalyst: Prime Medicine +12% breakout above the 50/200 DMAs, and mentions up 200% in 4 days on the gene-editing rotation as MRNA's cancer-vaccine Phase 3 read-through sparked newfound interest in the entire genetic-medicine complex — the sell side is small ($12M FY26 revenue estimate), so the tape is playing pipeline optionality.
  • The Beam Therapeutics arbitration win is a real legal signal: the arbitration tribunal declared that Prime Medicine's PM647 (an alpha-1 antitrypsin deficiency therapy) does not infringe Beam's IP — a specific legal clearing that removes a specific concentration risk on that pipeline asset, and the FDA cleared IND for PM577a in H1069Q-mutated Wilson Disease as another program advancement.
  • The short-squeeze structure is real: 35M short shares, 31% short interest with 10 days to cover and 0 shares available — a genuine squeeze setup that combined with the sector rotation is driving the tape; the multiple has no anchor in current-year revenue but plenty in FY28+ pipeline outcomes.

The setup is a hot-momentum gene-editing name coiled on a real squeeze structure plus favorable legal news — the November 6 Q3 print is the referee, and the market needs updated pipeline data (PM647, PM577a, or lead solid-tumor programs). A named clinical readout or an updated PowerCo-analog partnership breaks the coil up toward $6; another quarter of $1M revenue with no pipeline update kills the momentum.

Agrees with X sentimentThe bullish X read on the MRNA/MRK personalized cancer vaccine Phase 3 read-through sparking newfound interest in gene editing, +12% breakout above 50/200 DMAs, 35M short shares, 31% short interest (10 days to cover, 0 shares available), and mentions up 200% in 4 days is factually consistent with the tape. The "prime editing framed as God's technology" framing is aspirational but the squeeze structure is real.

What to watch: The November 6 Q3 earnings — need updated pipeline data (PM647, PM577a, or lead solid-tumor programs), and any updated PowerCo-analog partnership announcement. Another quarter of $1M revenue with no pipeline update kills the momentum; a named clinical readout or partnership breaks the coil up toward $6.

On the calendar: 2026-11-06 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment24 posts analyzed · as of 2026-08-30

Prime Medicine's thread turns emphatically bullish as posters flag zero short-shares-available on Fintel against 31-35M shares short and 10 days to cover, a break above the 50 and 200 EMA and mentions up 200% in four days. Bulls list the catalyst window: Wilson's first-in-human dosing, an AATD IND filing, additional CGD dosings and a potential BMY cash milestone. A few pleading posts fault management on the cash position; conviction otherwise dominates.

Read the AI verdict + X sentiment for $PRME

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRME.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $PRME

Partial — software subscription economics provide some insulation from macro cycles; AI integration is the growth catalyst for this segment; Prime Medicine, Inc.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-77.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-51.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
137.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-189%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.24$-0.26+6.7%
Q1 2026May 7, 2026$-0.28$-0.24-16.7%
Q4 2025Mar 3, 2026$-0.22$-0.25+12.0%
Q3 2025Nov 7, 2025$-0.32$-0.28-14.3%
Next earningsFri, Nov 6·consensus EPS $-0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$856K-41.1%-117%-5918%$-0.28$-42.9M
Q4 FY25$838K-61.6%100%-5800%$-0.26$-37.5M
Q3 FY25$1.2M+486.1%-3491%-4406%$-0.32$-35.3M
Q2 FY25$1.1M—-67.2%-4787%$-0.41$-43.0M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.2M$813K – $47.3M-$1.00-$1.19 – -$0.9110
FY27$21.0M$3.6M – $52.5M-$0.88-$1.11 – -$0.718
FY28$28.4M$3.3M – $114.8M-$0.80-$1.11 – -$0.5610
FY29$15.7M$1.8M – $63.6M-$0.91-$4.52 – $0.135
FY30$50.9M$6.0M – $206.2M-$0.82-$4.04 – $0.125

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.22%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+1.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 59.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (8 awards) in window

See when $PRME insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Prime Medicine, Inc. held its 2026 Annual Meeting on June 5, 2026, with 140.4 million of 180.6 million eligible shares represented (77.7%). Stockholders voted to elect Michael Kelly and David Schenkein, M.D. as Class I directors for terms through 2029, and to ratify PricewaterhouseCoopers LLP as auditor for fiscal 2026. Routine governance — no contested proposals.

3New insider — initial holdingsApr 173
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PRME on 2026-04-17, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 168-K — Item 5.02: Officer or director change
AI summary

PRME disclosed a personnel change (8-K Item 5.02, dated 2026-04-16). An executive departure and a new appointment are both reported. Svetlana Makhni as the Chief Financial. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Prime Medicine: Soon In The Clinicseekingalpha.com·16d agoPrime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimateszacks.com·25d agoPrime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Releasezacks.com·32d agoPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Diseaseglobenewswire.com·39d agoPrime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.defenseworld.net·42d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPRAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport